Clinical Trials Directory

If you agree to be in the study, you will have 1 study visit that will last about 4 hours. The visit will include asking questions about your medical history, vital signs, pulmonary function tests (PFTs) and an MRI (magnetic resonance image) of the chest with inhaled Xenon gas. Someone from the study team will contact you about 24 hours after your study visit.

We are doing this study to analyze biomarker responses to different drug regimens used for people who have HER2- and HER2+ breast cancer. We hope what we learn from the study can help us develop better treatments and figure out which treatment option(s) will be best for breast cancer patients.

We are doing this study to find the most effective, safe dose of an experimental drug called IAM1363 (the study drug) for people who have advanced cancers harboring HER2 alterations.

This study is a biorepository (storehouse) where samples and data from critically ill patients with COVID-19 are stored. The reason for this study is to develop a collection of samples and data that can be shared with other doctors and researchers to help them answer important questions about the virus and possibly help develop treatments and tests for the future. Este estudio es un registro central para guardar información y muestras de pacientes críticamente enfermos en una Unidad de Cuidados Intensivos (ICU) que tienen COVID-19 El objetivo de este estudio es crear una colección de información y muestras que pueda ser compartida con otros médicos y otros investigadores para ayudar a responder preguntas importantes sobre el virus, y posiblemente desarrollar tratamientos y pruebas de detección en el futuro.

Study visits at week 0, 4, 6, 8, and 12.

This study has three parts called screening, treatment or observation, and follow up. During screening, doctors will do tests and exams to see if a person can join. If they join the study, they will be placed into one of two groups by chance. One group will take two study medicines called darovasertib and crizotinib by mouth for up to about one year. The other group will not take study medicines but will be closely watched by doctors. Everyone in the study will have regular clinic visits with blood tests, scans, and eye exams. Doctors will continue to follow participants for several years, up to about six years, to see how they are doing and if the cancer comes back.

This study is being done to learn more about a vision problem called age related macular degeneration. It focuses on a late stage form called geographic atrophy, which can slowly damage vision. Researchers will follow people for at least six months and do tests to see how their vision changes over time. They will also look at genes, inflammation in the body, and lifestyle factors to see if these are linked to how the disease gets better or worse. The goal is to better understand this condition and help improve care in the future.